Although no large-scale studies have yet validated sAxl in GC, its established role in other aggressive malignancies—many of which share Axl-driven mechanisms of progression, invasion, and immune modulation—suggests it could serve as a surrogate marker for tumor burden and therapeutic response in GC as well. The gene discussed is AXL; the disease is neoplasm.